Monday, November 08, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
PoNS Market Authorization in Australia

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Australia Approval. Late last week, Helius announced it had received authorization from the Australian Therapeutic Goods Administration (TGA) for the sale of PoNS as a Class IIa (low-to-medium risk) medical device. Notably the authorization is for all indications, opening a much bigger market opportunity for the Company. In fact, the Australian market could be larger than the more populous Canadian market due to the Australian authorization.


Next Steps.  Helius is working with the TGA to finalize the exact scope of the authorization, which is expected to cover the use of PoNS to improve balance and gait when used as an adjunct to a therapeutic exercise program. Helius will begin evaluating the pathway toward commercialization in Australia once the scope of the authorization is finalized …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.